CLYBL and neuroblastoma: Similarly to the lymphoma subtype, both ALK-driven NSCLC and neuroblastoma, previously incubated with short-term TKIs (20 h of alectinib or lorlatinib for H3122 and 20 h of lorlatinib for CLB-Ga), were more susceptible to phagocytosis with anti-CD47 mAb during co-culture assay (Figure 3C and Figure S7).